Companies / Aura Biosciences, Inc.

Aura Biosciences, Inc.

Nasdaq: AURACIK 1501796BOSTON, MA

Financials

Revenue—
Net income$-106.19M
Total debt—
Cash$67.84M
Diluted EPS$-1.76
Shares outstanding103.7M

Ownership

103.7M shares outstanding · as of Aug 6, 2026
1.7%Insiders
Ownership
Insiders1.71%1,768,702
Institutions50.77%52,652,126
Public float47.52%49,283,981

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 6

View all →
Insider% of sharesShares
de los Pinos ElisabetSee Remarks · Director
0.56%575,815
Hopkins Janet JillChief Medical Officer
0.31%321,340
Gibney Anthony SSee Remarks
0.27%278,178
Plavsic MarkChief Technology Officer
0.24%243,736
Kilroy ConorSee Remarks
0.22%229,573
Elazzouzi AmySenior Vice President, Finance
0.12%120,060

Institutional holders 122

View all →
HolderValue% of shares
Matrix Capital Management Company, LP$37.73M6.68%
BlackRock, Inc.$33.42M4.54%
Adage Capital Partners Gp, L.L.C.$32.65M4.71%
Frazier Life Sciences Management, L.P.$27.80M4.92%
Long Focus Capital Management, LLC$25.18M4.45%
Suvretta Capital Management, LLC$23.83M4.22%
Medicxi Ventures Management (Jersey) Ltd$16.57M2.93%
Vanguard Group Inc$16.00M2.83%
Franklin Resources, Inc.$11.98M2.12%
Nantahala Capital Management, LLC$11.54M2.04%

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q2 2026
as of
BlackRock, Inc.
13F manager
AddCommon Stock$8.15M+1.1M
+32.22%
4,707,674
4.54% of shares
medium
Q1 2026
as of
Balyasny Asset Management L.P.
13F manager
NewCommon Stock$3.73M+558K
557,654
0.54% of shares
low
Q1 2026
as of
Millennium Management LLC
13F manager
AddCommon Stock$3.21M+480K
+77.80%
1,097,627
1.06% of shares
low
Q2 2026
as of
State Street Corporation
13F manager
AddCommon Stock$2.10M+296K
+32.00%
1,222,984
1.18% of shares
low
Q4 2025
as of
Bank of America Corp /De
13F manager
AddCommon Stock$703.1K+129K
+356.53%
165,185
0.16% of shares
low
Q1 2026
as of
Levin Capital Strategies, L.P.
13F manager
TrimCommon Stock$-630.1K-94K
-9.09%
941,400
0.91% of shares
low
Q3 2024
as of
Barclays PLC
13F manager
AddCommon Stock$391.1K+44K
+256.51%
61,010
0.06% of shares
low
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon Stock$370.7K+55K
+4.41%
1,310,862
1.26% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Frazier Life Sciences Public Fund, L.P.Passive13G/A———
Advent Life Sciences LLPPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
AURACommon StockEquity05153U107BBG00226DGM5